Trial · NCT01975519
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicity (DLT) | TRC105 Plus Pazopanib | Patients with DLT at 8 mg/kg | 0 | Participants | |
| Number of Participants With Dose Limiting Toxicity (DLT) | TRC105 Plus Pazopanib | Patients without DLT at 8 mg/kg | 3 | Participants | |
| Number of Participants With Dose Limiting Toxicity (DLT) | TRC105 Plus Pazopanib | Patients with DLT at 10 mg/kg | 1 | Participants | |
| Number of Participants With Dose Limiting Toxicity (DLT) | TRC105 Plus Pazopanib | Patients without DLT at 10 mg/kg | 22 | Participants | |
| Progression Free Survival of Patients With Advanced Soft Tissue Sarcoma (Phase 1 and 2) | 8 mg/kg TRC105 + Pazopanib | 5.06 | 95% Confidence Interval 4.96 to NA | months | |
| Progression Free Survival of Patients With Advanced Soft Tissue Sarcoma (Phase 1 and 2) | 10 mg/kg TRC105 + Pazopanib | 3.45 | 95% Confidence Interval 2.56 to 3.85 | months | |
| Objective Response Rate in a Cohort of Patients With Angiosarcoma | 10 mg/kg TRC105 + Pazopanib With Angiosarcoma | Complete Response (CR) | 2 | Participants | |
| Objective Response Rate in a Cohort of Patients With Angiosarcoma | 10 mg/kg TRC105 + Pazopanib With Angiosarcoma | Partial Response (PR) | 0 | Participants | |
| Objective Response Rate in a Cohort of Patients With Angiosarcoma | 10 mg/kg TRC105 + Pazopanib With Angiosarcoma | Stable Disease (SD) | 3 | Participants | |
| Objective Response Rate in a Cohort of Patients With Angiosarcoma | 10 mg/kg TRC105 + Pazopanib With Angiosarcoma | Progressive Disease (PD) | 0 | Participants | |
| Objective Response Rate in a Cohort of Patients With Angiosarcoma | 10 mg/kg TRC105 + Pazopanib With Angiosarcoma | Not Evaluable | 0 | Participants | |
| Trough Concentrations of TRC105 (Phase 2) | 10 mg/kg TRC105 + Pazopanib | Cycle 2 Day 1 (4 weeks) trough PK concentrations | 124 | Full Range 80 to 174 | ug/mL |
| Trough Concentrations of TRC105 (Phase 2) | 10 mg/kg TRC105 + Pazopanib | Cycle 2 Day 15 (6 weeks) trough PK concentrations | 86 | Full Range 62 to 144 | ug/mL |
| Trough Concentrations of TRC105 (Phase 2) | 10 mg/kg TRC105 + Pazopanib | Cycle 3 Day 1 (8 weeks) trough PK concentrations | 91 | Full Range 73 to 121 | ug/mL |
| Trough Concentrations of TRC105 (Phase 2) | 10 mg/kg TRC105 + Pazopanib | Cycle 3 Day 15 (10 weeks) trough PK concentrations | 80 | Full Range 63 to 100 | ug/mL |
| Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | 8 mg/kg TRC105 + Pazopanib | Pt with treatment emergent ADA | 1 | Participants | |
| Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | 10 mg/kg TRC105 + Pazopanib | Pt with treatment emergent ADA | 12 | Participants | |
| Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | 8 mg/kg TRC105 + Pazopanib | Pt without treatment emergent ADA | 2 | Participants | |
| Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | 10 mg/kg TRC105 + Pazopanib | Pt without treatment emergent ADA | 67 | Participants | |
| Number of Patients With and Without Expression of Endoglin on Sarcoma Tissue (Phase 1 and 2) | TRC105 Plus Pazopanib | Tumor endoglin expression positive | 15 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01975519/results